Peply - The FDA Approval Process: Why Most Peptides Never Get Approved

The 12-Year, $2.6 Billion Gauntlet

Getting a new drug FDA-approved is one of the most expensive, risky, and time-consuming processes in regulated industries. The average drug takes 10-15 years of development and costs roughly $2.6 billion (counting failures). For peptides specifically, the math often doesn't work — and that's why the grey market exists.

The 5 Stages of FDA Approval

Preclinical Research (1-3 years)
Lab studies and animal testing. Must show the compound has a plausible mechanism and isn't obviously toxic. Costs: tens of millions.
Phase I — Safety (1-2 years, 20-100 healthy volunteers)
Does it kill people at any dose? What are the basic pharmacokinetics? Success rate: ~70%.
Phase II — Efficacy (2-3 years, 100-500 patients)
Does it actually work on the target condition? Success rate: ~33%.
Phase III — Large Trials (3-5 years, 1,000-5,000+ patients)
Definitive evidence it works better than placebo (or the existing standard of care). Success rate: ~60%.
NDA Submission & Review (1-2 years)
FDA reviews thousands of pages of data. ~85% of submissions that make it this far are eventually approved.

Overall success rate from Phase I to approval: roughly 10-12%.

Why Peptides Specifically Fail the Business Case

Many peptides have excellent science behind them. BPC-157 has decades of research showing profound healing properties — yet it's never been FDA-approved. Why?

1. Patents Don't Cover What's Natural

Most peptides are identical to sequences your body already makes. You can't patent a naturally-occurring molecule. Without a 20-year monopoly, there's no guaranteed way to recoup $2B.

2. Compounding Pharmacies Undercut Pricing

If a company spends billions developing a peptide, compounding pharmacies can legally sell the same molecule (once on the market) for a fraction of the price — or the formula leaks and generics emerge immediately. The ROI math collapses.

3. Injections Are Hard to Commercialize

Most peptides must be injected — they're destroyed in the gut. Injectables have smaller addressable markets than pills. Patients want convenience, not syringes.

4. The Approval Timeline Exceeds Peptide Markets

By the time a peptide passes 12 years of FDA review, the company funding it may have folded, or better analogs (Tirzepatide before Retatrutide) may have eaten the market.

The Exceptions: When It Does Happen

A few peptides have cracked the code:

Semaglutide (Ozempic/Wegovy) — Novo Nordisk; massive obesity market, modified for stability, blockbuster economics
Tirzepatide (Mounjaro/Zepbound) — Eli Lilly; dual-action patent, $1B+ yearly revenue already
Tirzepatide's cousin Retatrutide — triple-action, in Phase 3 now
Tesamorelin (Egrifta) — orphan drug status for HIV lipodystrophy, got through
Thymalfasin (Thymosin Alpha-1) — FDA-approved overseas, niche use in US

The pattern: either huge markets (obesity/diabetes) or regulatory loopholes (orphan drug designation) make the math work.

The Result: A Grey Market

For decades, researchers and biohackers have used peptides based on preliminary science — without waiting for FDA approval. These products are sold as "research chemicals," legally labeled "not for human consumption," but everyone knows what they're for.

Is this system perfect? Absolutely not. But it's the rational economic outcome of rules written for big pharma in a world where peptides don't fit the mold.

Read next: The Grey Market →